IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors

Inclusion Criteria

• Patients with advanced and/or metastatic histologically solid tumors with evidence of active disease, who have been treated with a minimum of one line of systemic therapy in the metastatic setting, and in expansion part, no more than two prior systemic therapies.
• At least 18 years of age.
• ECOG performance status of ≤1.
• Adequate organ function

Exclusion Criteria

• For patients with Non Small Cell Lung Cancer (NSCLC): a. Known actionable mutation or rearrangement (including but not limited to the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) gene rearrangements, ROS-1 alterations or BRAF mutations)
• For patient with Hepatocellular carcinoma (HCC):
• Hepatic encephalopathy in the past 12 months.
• Ascites that requires repeated paracentesis in the past 2 months.
• Main portal vein thrombosis.
• Active or prior history of gastrointestinal bleeding in the past 12 months.
• Prior hepatic transplantation.
• Patients with known spinal cord compression.
• Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.